已收盤 11-20 16:00:00 美东时间
-0.440
-5.99%
11月19日,Kura Oncology Inc(KURA)收跌2%,报7.34美元,成交额1874.68万美元,市值6.74亿美元。 行情数据 • 开盘价:...
11-19 06:56
Kura Oncology announced that its management will present at two investor conferences: the UBS Global Biopharma London Conference on November 17, 2026, and the Jefferies Global Healthcare Conference on November 18, 2026. Live audio webcasts will be available on Kura’s website, with archived replays following the events. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline targeting cance...
11-13 17:33
11月11日,Kura Oncology Inc(KURA)收平,报7.57美元,成交额1882.43万美元,市值6.73亿美元。 行情数据 • 开盘价:7....
11-11 06:55
Kura Oncology Files Shelf Prospectus For Offering; Size Not Disclosed
11-11 06:22
Kura Oncology reported strong Q3 2026 performance with KOMZIFTI net product revenue up 53% to $13.9M, new patient starts up 30%, and total prescriptions up 65%. KOMZIFTI maintained majority share in the R/R NPM1-m AML market. The company advanced ziftomenib into frontline AML and reached FDA alignment on a darlifarnib registrational study for HRAS-mutant salivary gland cancer. Financially, Kura has $492.1M in cash and secured up to $300M addition...
11-10 21:02
Kura Oncology granted inducement stock options to three new employees under its 2023 Inducement Option Plan. The options, totaling 55,500 shares with an exercise price of $9.79 per share, vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next 36 months. The grant aligns with Nasdaq Listing Rule 5635(c)(4).
11-06 12:30
11月5日,Kura Oncology Inc(KURA)收跌22.98%,报7.61美元,成交额6710.41万美元,市值6.77亿美元。 行情数据 • 开盘...
11-05 06:57
MacroGenics, Inc. announced the appointment of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors to its Board of Directors, effective October 30, 2026. Both bring extensive oncology drug development experience, which will support the company's pipeline advancement and long-term strategic goals. Dr. Kuriakose has over a decade of experience in oncology and metabolic disease drug development, most recently as Chief Medica...
11-03 21:05
Kura Oncology announced it will report third quarter 2026 financial results after market close on November 10, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. The live webcast and archived replay will be available on the Company’s website. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer, with a pipeline targeting c...
11-03 11:58
10月29日,Kura Oncology Inc(KURA)收涨8.28%,报10.72美元,成交额2392.15万美元,市值9.54亿美元。 行情数据 • 开...
10-29 05:46